Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Hill

Showing results (11-20 of 593) with videos related to

Pageof 60
Sort By:
AIDS (London, England)|January 26, 2005
Short-course induction with boosted saquinavir monotherapy for naive patients with late-stage infectionOsman Ebrahim, Andrew Hill
Journal of Virus Eradication|December 6, 2018
Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countriesJoel Sim, Andrew Hill
AIDS (London, England)|May 19, 2010
A normal life expectancy, despite HIV infection?Andrew Hill, Anton Pozniak
AIDS (London, England)|January 27, 2007
Balancing effectiveness and access to HIV treatment in the developing worldAndrew Hill, Evan Wood
European Journal of Hospital Pharmacy : Science and Practice|March 31, 2022
Analysing electronic prescribing data to detect potential undocumented adverse reactions to medicationsBen Logan, Andrew Hill
The American Journal of Managed Care|September 7, 2007
Predicting HIV care costs using CD4 counts from clinical trialsAndrew Hill, Kelly Gebo
The Journal of Antimicrobial Chemotherapy|December 28, 2022
The dangers of non-randomized, observational studies: experience from the COVID-19 epidemicAndrew Hill, Manya Mirchandani
Current Opinion in Infectious Diseases|December 5, 2020
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapyShahini Shah, Andrew Hill
AIDS (London, England)|May 6, 2008
Designing and interpreting HIV noninferiority trials in naive and experienced patientsAndrew Hill, Caroline Sabin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2026
What Are the Causes and Consequences of Virological Failure on Long-acting Cabotegravir/Rilpivirine?Andrew Hill, Chloe Orkin
Pageof 60

Showing results (11-20 of 593) with videos related to

Sort By:
Pageof 60
AIDS (London, England)|January 26, 2005
Short-course induction with boosted saquinavir monotherapy for naive patients with late-stage infectionOsman Ebrahim, Andrew Hill
Journal of Virus Eradication|December 6, 2018
Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countriesJoel Sim, Andrew Hill
AIDS (London, England)|May 19, 2010
A normal life expectancy, despite HIV infection?Andrew Hill, Anton Pozniak
AIDS (London, England)|January 27, 2007
Balancing effectiveness and access to HIV treatment in the developing worldAndrew Hill, Evan Wood
European Journal of Hospital Pharmacy : Science and Practice|March 31, 2022
Analysing electronic prescribing data to detect potential undocumented adverse reactions to medicationsBen Logan, Andrew Hill
The American Journal of Managed Care|September 7, 2007
Predicting HIV care costs using CD4 counts from clinical trialsAndrew Hill, Kelly Gebo
The Journal of Antimicrobial Chemotherapy|December 28, 2022
The dangers of non-randomized, observational studies: experience from the COVID-19 epidemicAndrew Hill, Manya Mirchandani
Current Opinion in Infectious Diseases|December 5, 2020
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapyShahini Shah, Andrew Hill
AIDS (London, England)|May 6, 2008
Designing and interpreting HIV noninferiority trials in naive and experienced patientsAndrew Hill, Caroline Sabin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2026
What Are the Causes and Consequences of Virological Failure on Long-acting Cabotegravir/Rilpivirine?Andrew Hill, Chloe Orkin
Pageof 60